Featured Research

from universities, journals, and other organizations

New anti-tumor cell therapy strategies are more effective

Date:
October 25, 2012
Source:
Mary Ann Liebert, Inc., Publishers
Summary:
Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in two new studies.

Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Related Articles


Richard Morgan and colleagues from the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, and Duke University Medical Center, Durham, NC, used engineered T-cells to attack glioma stem cells, which are one of the cell types present in glioblastoma, an aggressive and fatal type of brain cancer. There is no curative treatment for glioblastoma, and patients usually live less than two years from diagnosis. In the article "Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma," the authors describe how targeting tumor stem cells, in combination with traditional therapies aimed at killing other types of glioma tumor cells, could improve the effectiveness of treatment and reduce tumor recurrence.

In a related article, Karen Kaluza and coauthors, Mayo Clinic, Rochester, MN, conducted a study using T-cells capable of recognizing two different antigens simultaneously and showed that this dual targeting strategy could be more effective at clearing tumor cells and reducing the risk of "tumor escape" and cancer recurrence. In "Adoptive Transfer of Cytotoxic T Lymphocytes Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape," the authors conclude that T-cell therapies targeting two or more antigens will have significant added value compared to single-antigen therapies.

"These studies represent important advances in the development of novel treatments for cancer that combine the power of gene transfer and cell transplantation," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.


Story Source:

The above story is based on materials provided by Mary Ann Liebert, Inc., Publishers. Note: Materials may be edited for content and length.


Journal References:

  1. Richard A. Morgan, Laura A. Johnson, Jeremy L. Davis, Zhili Zheng, Kevin D. Woolard, Elizabeth A. Reap, Steven A. Feldman, Nachimuthu Chinnasamy, Chien-Tsun Kuan, Hua Song, Wei Zhang, Howard A. Fine, Steven A. Rosenberg. Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma. Human Gene Therapy, 2012; 23 (10): 1043 DOI: 10.1089/hum.2012.041
  2. Karen M. Kaluza, Timothy Kottke, Rosa Maria Diaz, Diana Rommelfanger, Jill Thompson, Richard Vile. Adoptive Transfer of Cytotoxic T Lymphocytes Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape. Human Gene Therapy, 2012; 23 (10): 1054 DOI: 10.1089/hum.2012.030

Cite This Page:

Mary Ann Liebert, Inc., Publishers. "New anti-tumor cell therapy strategies are more effective." ScienceDaily. ScienceDaily, 25 October 2012. <www.sciencedaily.com/releases/2012/10/121025112923.htm>.
Mary Ann Liebert, Inc., Publishers. (2012, October 25). New anti-tumor cell therapy strategies are more effective. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2012/10/121025112923.htm
Mary Ann Liebert, Inc., Publishers. "New anti-tumor cell therapy strategies are more effective." ScienceDaily. www.sciencedaily.com/releases/2012/10/121025112923.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins